EQL Pharma is preparing a listing on Nasdaq Stockholm

Report this content

The Board of Directors of EQL Pharma AB (publ) ("EQL Pharma" or "the Company") has decided to evaluate the conditions for listing the Company's share on Nasdaq Stockholm's main list. The list change is expected to take place during the last quarter of 2020.

EQL Pharma's share has been listed on Spotlight Stock Market since 2013 and in Spotlight's new segment Next since October 31, 2019. Companies traded in this segment follow stricter rules regarding, among other things, accounting principles than other companies listed on Spotlight Stock Market. The requirements correspond in several respects to the requirements set out on Nasdaq Stockholm's main list.

The Company's Board of Directors and management will now initiate the work required to prepare the Company for a listing on Nasdaq Stockholm. The goal is to carry out the list change during the last quarter of 2020.

“We believe that EQL Pharma is ready to be listed on Nasdaq Stockholm's main list. A listing on Nasdaq Stockholm is a quality stamp and with the list change we are now taking the next step to gain access to the international capital market and facilitate for more institutional investors to become owners of the company, ”says Christer Fåhraeus, CEO of EQL Pharma.

EQL Pharma has hired the law firm HWF Advokater as legal advisor for the planned list change.

This information is information that EQL Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 9:40 CET on December 20th, 2019.

For further information, please contact: 
Christer Fåhraeus
CEO EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com 

About EQL Pharma 
EQL Pharma AB is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently has 18 niche generics (i.e. generics with little or no competition except for the original medicine) approved on the Swedish and Danish markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2020 and onwards. The business is currently entirely focused on prescription pharmaceuticals. EQL Pharma AB is based in Lund, Sweden, employs 9 people and is listed on Spotlight Stock Market. EQL Pharma AB also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China. 


Documents & Links